ZIA CP010145 07210 (ZIA) | |||
---|---|---|---|
Title | National Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Ovarian Scr | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Greene, Mark | NCI Program Director | N/A |
Cancer Activity | N/A | Division | DCEG |
Funded Amount | $102,407 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Basic Behavioral and Social Science (100.0%) Biochemical Epidemiology (45.0%) Cancer (100.0%) Behavioral and Social Science (100.0%) |
Breast (20.0%) Ovarian Cancer (80.0%) |
||
Research Type | |||
Endogenous Factors in the Origin and Cause of Cancer Interventions to Prevent Cancer: Personal Behaviors (Non-Dietary) that Affect Cancer Risk |
|||
Abstract | |||
The <B>GOG-0199 National Ovarian Cancer Prevention and Early Detection Study</B> among women at increased genetic risk of ovarian cancer accomplishments include: (1) a baseline report detailing study design and baseline subject characteristics; (2) analysis of baseline CA-125 level determinants which demonstrated that pre-menopausal women should have an upper limit of normal cut-off=52; (3) creating a biospecimen repository for future translational research; (4) publishing 40 manuscripts with CIMBA, plus 8 more are under review; (5) The definitive CIMBA genotype/phenotype analysis of breast and ovarian cancer risk in 30,000 BRCA mutation carriers has been published in JAMA. Our report describing that invasive or intraepithelial ovarian/tubal/peritoneal neoplasms were detected in 25 (2.6%) of 966 GOG-09199 RRSOs (<i>BRCA1</i> carriers=4.6%, <i>BRCA2</i> carriers=3.5%, and non-carriers=0.5% (p=0.0006) provides the best current prevalence estimates for clinically-occult serous pelvic malignancy at the time of RRSO. Our Commentary proposing that bilateral salpingectomy may represent a viable alternative to RRSO has led to the development of a GOG-based pilot study to test the feasibility and physical consequences of this hypothesis. Additional analyses underway: (1) ROCA ovarian cancer screening algorithm performance characteristics; (2) testing/validation of the surgery vs. screening medical decision-making choice; (3) baseline quality of life by study arm; (4) blinded pathology review of RRSO surgical pathology material targeting proliferative fallopian tube mucosa lesions; (5) prospective breast, ovarian cancer incidence in GOG-0199; (6) ovarian size vs. circulating ovarian hormone levels; and (7) results of a novel ovarian cancer surface epithelial cell collection method. Multiple biospecimen-based translational research projects are both underway and planned. Primary protocol endpoint analyses have resulted in 3 manuscripts, with another 3 in the pipeline. |